Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Awesome- Thanks! I have discussed the weakness of Valvide in the past and the data. But after looking into where AGO13 is, I think we are a could lap ahead too.

Oragenics believes they can complete their phase 2 trial by the end of 2018.

Here is phase 1b:
In a phase 1B clinical trial in 25 cancer patients with OM, AG013 was safe and well tolerated. Data published in the journal Cancer showed a 35% reduction of the duration of ulcerative OM in the AG013-treated patients versus the placebo-treated patients. Furthermore, close to 30% of the patients treated with AG013 were full responders while all placebo-treated patients developed ulcerative OM.
https://www.oragenics.com/technology-pipeline/lbp/ag013

Here is the current criteria on CLINICALTRIALS.gov

https://clinicaltrials.gov/ct2/show/NCT03234465?term=AG013&recrs=ab&rank=1

It is different than B-OM. Our primary was much more defined as preventative. IMO

I think you are right about taking a HUGE backend royalty and lesson the load of upfront for B-OM.

Awesome stuff and it appears from all of my DD - that B-OM could take the market first!